Name: E2027
Therapy Type: Small Molecule (timeline)
Target Type: Other (timeline)
Condition(s): Dementia with Lewy Bodies
U.S. FDA Status: Dementia with Lewy Bodies (Phase 2)
Company: Eisai Co., Ltd.


E2027 is a selective inhibitor of phosphodiesterase 9. PDE9 is an enzyme that breaks down cyclicGMP, cGMP, which serves as a second messenger in synaptic function and memory. E2027 is intended to boost brain cGMP levels to improve cognition.
No peer-reviewed preclinical studies of E2027 are formally published. In meeting presentations, Eisai scientists reported the drug is 1,000-fold selective for PDE9A over other PDE family members, with a 50 percent inhibitory concentration of 3.5 nM. In rats, single and multiple oral doses were claimed to increase cGMP concentrations in CSF and hippocampus, and to improve performance in tests of natural memory, as well as in a model of scopolamine-induced amnesia (Ando et al., 2017; Ando et al., 2018).

Eisai discovered E2027 and is developing it to treat dementia with Lewy bodies, a disease marked by α-synuclein deposits in brain neurons. Phosphodiesterase inhibition has been claimed to ameliorate α-synuclein toxicity in cell-based assays (Höllerhage et al., 2017).

Development of two prior PDE9A inhibitors for Alzheimer’s disease ended after they failed to improve symptoms in Phase 2 (see BI 409306 and Aug 2011 news).  


In 2015 and 2016, Eisai ran a Phase 1 trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of E2027 in 112 healthy adults. Part A of this four-part study gave single ascending doses of 10 to 1,200 mg to non-elderly volunteers, Part B examined the effect of food, Parts C and D tested single doses in healthy elderly and in non-elderly Japanese volunteers. Target engagement was determined by measuring cGMP concentrations in CSF. Results of the single-dose study were presented at the 2017 Alzheimer’s Association International Conference (Aug 2017 conference news). The drug was well-tolerated at all doses. It was absorbed quickly, reaching maximum blood levels in under less than hours. Blood levels were increased by food; pharmacokinetics were similar in different ethnicities. Single doses of 100 and 400 mg led to three- to fourfold increases in CSF cGMP.

From August 2016 to November 2017, a second Phase 1 trial evaluated multiple doses in 74 healthy older adults, who received 5 to 400 mg drug or placebo once daily for two weeks, or 50 mg daily for six weeks. Primary outcomes were PK measurements; secondary measures included CSF cGMP. According to trial results presented at the 2018 AAIC, all doses were well-tolerated (abstract). Blood levels of drug reached steady-state after seven days, with 3.5 percent of plasma concentration reaching the brain. The drug caused a dose-dependent increase in CSF cGMP, which was maximal at 50 mg and sustained over the six-week regimen. 

A third Phase 1 study in 16 healthy volunteers showed no clinically significant interaction of E2027 with diltiazem, a calcium channel blocker commonly used to treat high blood pressure, angina, and some heart arrhythmias (see 2018 AAIC abstract). A fourth study tracked elimination of radioactively labeled drug in eight volunteers; it concluded in October 2019 but results have not been made public. 

In May 2018, a Phase 2/3 trial began enrolling 206 participants with dementia with Lewy bodies for 12 weeks of treatment with 50 mg E2027 daily, or placebo. The two primary outcomes are the Montreal Cognitive Assessment (MoCA) and the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBICPlus); secondary outcome measures include the Neuropsychiatric Inventory, MMSE, and Cognitive Fluctuations Inventory. The trial is being run at 74 locations in the U.S., Europe, and Japan, and completed recruiting in December 2019. The study end date was set for mid-2020, but in February 2020 that was changed to July 2025.  

For details on E2027 trials, see

Last Updated: 18 Sep 2020


No Available Comments

Make a Comment

To make a comment you must login or register.


News Citations

  1. At AAIC, Encouraging Safety Data on a Variety of Small-Molecule Candidates
  2. Paris: More Trial News, Mixed at Best

Therapeutics Citations

  1. BI 409306

Paper Citations

  1. . Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells. Sci Rep. 2017 Sep 13;7(1):11469. PubMed.

External Citations

  1. abstract
  2. 2018 AAIC abstract
  4. Ando et al., 2017
  5. Ando et al., 2018

Further Reading

No Available Further Reading